Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.


Guidelines for Authors

Conflicts of Interest
Peer-Review Policy
Plagiarism Policy
Color Illustrations
Digital Object Identifier (DOI)
Supplementary Material
Self-Archiving/Green Open Access, Author's ChoiceTM,
   Funding Organizations (NIH etc.)

Page Charges
Uniform Clinical Trial Registration Policy for Journals of
   Kidney Diseases, Dialysis and Transplantation


Manuscripts in English should be submitted online.

Should you experience any problems with your submission, please contact the Managing Editor, Manuela Passera


Tel. +39 035 4213405
Fax +39 035 319331

Original papers: Submitted manuscripts should be fully documented reports of original research. They must describe significant and original observations to be critically evaluated and, if necessary, repeated.

Clinical trial protocols will only be considered if the trial has been fully registered (see A Uniform Clinical Trial Registration Policy for Journals of Kidney Diseases, Dialysis and Transplantation below).

Reviews/Minireviews: Are to be submitted only by invitation, although prospective authors are welcome to contact the Managing Editor to discuss whether a topic might be suitable for a Review. The maximum length of a Review/Minireview should be 3,500/2,000 words including abstract and discussion, excluding figure legends and references (50/25 references maximum).

Editorial and Second Opinion: The maximum length of an Editorial/Second Opinion article should be 1,500/2,500 words including abstract, integrated discussion, excluding references (25/40 references maximum).

Case studies of genetic interest: the objective of such papers in the section Experimental Nephrology and Genetics is to provide clinically relevant examples of the genetic heterogeneity of renal diseases. Therefore, reports of cases with an unusual genotype/phenotype correlation, or clinical pictures that revealed an unexpected genetic basis are welcome. Also, functional studies of genetic forms of renal diseases shedding light on the disease mechanism are appropriate for submission in this section. Outside this scope Nephron does not publish any case reports. The authors of case reports are invited to submit their manuscript to the Open Access journal Case Reports in Nephrology and Dialysis at www.karger.com/cnd.

Letters to the Editor: Letters in reference to a journal article must not exceed 200 words (excluding references) and should be received within 2 months after publication of the article. Letters not related to a journal article must not exceed 400 words (excluding references). Letters can have a maximum of five references and one figure or table. They should not be signed by more than three authors.

Conditions and review

All manuscripts are subject to independent and editorial review.

Upon submission, each manuscript is evaluated by the editors and the authors are informed whether the manuscript will be further processed.

Before being forwarded to the Associate Editors and reviewers, the presentation of the paper (organization of the results, quality of the figures, overall writing quality, etc.) is assessed and summarized in a Presentation Report that is fair, professional and standardized. The Presentation Report follows the manuscript throughout the peer review and supports editors, reviewers, and authors in the review process.

The Editors and Associate Editors carefully analyse the comments of the reviewers in order to provide the authors with constructive and realistic requests that should be feasible within the 12 weeks of revision time. The requests made to the authors by the editors are aimed to improve the robustness and significance of the data presented in the manuscript, while curtailing excessive demands in term of effort, time and cost.

Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Nephron and may not be reproduced by any means, in whole or in part, without the written consent of the publisher.

For legal reasons, we must receive your 'Submission Statement' with your original (hand-written) signature. Please download, print, sign and either fax or scan it to make it legally binding.

It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflicts of Interest

Any financial (funding, stocks, patents, employment, honoraria, royalties) or non-financial (political, personal, professional) interests/relationships that may be interpreted to have influenced the manuscript must be identified in a 'Conflicts of Interest Statement'. If there are no conflicts of interest, please state "The authors declare no conflicts of interest". Conflict of interest statements will be published at the end of the article.

Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation.
If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).


Published research must comply with the guidelines for human studies and animal welfare regulations. Manuscripts reporting studies on human subjects should include evidence that the research was ethically conducted in accordance with the World Medical Association Declaration of Helsinki (http://www.wma.net/en/30publications/10policies/b3/index.html). In particular, authors must provide a 'Statement of Ethics' at the end of the manuscript and declare that subjects (or their parents or guardians) have given their informed written consent and that the study protocol was approved by an appropriate ethics committee. If no approval was required, this must be stated in this section. All patients should be identified by numbers or aliases, not by their real names. For clinical trials, registration in a public trials registry at or before the time of first patient enrollment is a condition of consideration for publication. The trial registration number must be provided upon submission. Authors should also state that animal experimentation was approved by the appropriate institutional review body. Copies of these guidelines and policy statements must be available for review by the editors if necessary. Authors are encouraged to follow the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (https://www.nc3rs.org.uk/arrive-guidelines) for reporting on animal studies.

Peer-Review Policy

Nephron is a peer-reviewed journal that uses a single-blind peer-review. Our aim is to provide authors with fast and constructive feedback regarding their submitted manuscript. The Editor-in-Chief and the international editorial board ensure a thorough and fair peer-review and the highest scientific publishing standards. Editors guide the peer-review process for papers in their areas of expertise. They select reviewers and make the decision whether to accept/reject or send a manuscript for revision after at least two review reports are received, and then a further decision to accept/reject or request further revisions following author revisions. Reviewers must have a recent publication record in the area of the submission, must not have published with the authors in the previous three years, and must not be from the same institution as the authors. The Editor-in-Chief is responsible to maintain high-quality peer-review of papers submitted to the journal.


Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, a short title for use as running head (max. 80 characters), the word count and the total number of references.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone number and well as e-mail address.

Units: Nephron requires that all articles be submitted with data in SI units and gravimetric units.

Key words:Please supply 3–10 key words in English that reflect the content of the paper

Abstract: Each paper needs an abstract of up to 250 words. It should be structured as follows:
   Background/Aims: What is the major problem that prompted the study?
   Methods: How was the study carried out?
   Results: Most important findings?
   Conclusion: Most important conclusion?

Abstracts in Case Studies of genetic interest need not be structured.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables are part of the text. Place them at the end of the text file. Illustration data must be stored as separate files. Do not integrate figures into the text. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi.

Color Illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.


In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Number references in the order in which they are first mentioned in the text; do not list alphabetically. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).


(a) Papers published in periodicals:
Robinson CM, O’Dee D, Hamilton T, Nau GJ: Cytokines involved in interferon-γ production by human macrophages. J Innate Immun 2010;2:56–65.

(b) Papers published only with DOI numbers:
Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

(c) Monographs:
Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996.

(d) Edited books:
Kashihara N, Sugiyama H, Makino H: Implication of apoptosis in progression of renal diseases; in Razzaque MS, Taguchi T (eds): Renal Fibrosis. Contrib Nephrol. Basel, Karger, 2003, vol 139, pp 156–172.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org

Supplementary Material

Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 MB in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license.

Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

  • Be used for noncommercial purposes only
  • Be linked to the final version on www.karger.com
  • Include the following statement:

‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author's ChoiceTM (Gold Open Access) articles, see Author's ChoiceTM.

Author's ChoiceTM

Karger’s Author's ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.
The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

  • Follow the terms of the relevant Creative Commons license
  • Be linked to the final version on www.karger.com
  • Include the following statement:

‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's ChoiceTM, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC.
Authors should include information on their grant in the Acknowledgements section of their papers.

Page Charges

There are no page charges for papers of 3 or fewer printed pages (including tables, figures, references and acknowledgements). Each additional complete or partial page is charged to the author at CHF 375.–.


Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer's errors are charged to the author.


Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

A Uniform Clinical Trial Registration Policy for Journals of Kidney Diseases, Dialysis and Transplantation

Clinical trials provide important information that can profoundly influence the direction of medical research and clinical care. It is crucial that this process is not unduly influenced by selective publication of clinical trial results. Information regarding all clinical trials should therefore be made available to the general public.

In common with other nephrology journals, Nephron requires that from 2006 all submitted manuscripts concerning clinical trials must be registered in a public trials registry.

The full text of a recent statement published by the editors of: Kidney International; The Journal of the American Society of Nephrology; Nephrology, Dialysis, Transplantation; The American Journal of Transplantation; The American Journal of Kidney Diseases, and Transplantation is reproduced below. The policy described in this text has now been formally adopted by Nephron.

Medical research can be seriously compromised by the selective publication of clinical trial results. Therefore, it is imperative that information regarding clinical trials should be available to the general public.

We require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. Since 1 April 2006, Nephron no longer accepts manuscripts concerning non-registered trials.

We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase 1 trials) are exempt.

We do not advocate any one particular registry, but registration must be with a registry that meets the following minimum criteria:
  • Accessible to the public at no charge.
  • Searchable by standard, electronic (internet-based) methods.
  • Open to all prospective registrants free of charge or at minimal cost.
  • Validates registered information.
  • Identifies trials with a unique number.
  • Includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).

Registries that currently meet these criteria include: